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ABSTRACT  43 
Insertion of a single chain antibody (scFv) to HER2 (human epidermal growth factor receptor 2) in 44 
gD, gH, or gB gives rise to herpes simplex viruses (HSVs) specifically retargeted to HER2-positive 45 
cancer cells, hence in highly specific non-attenuated oncolytic agents. Clinical grade virus 46 
production can not rely on cancer cells. Recently, we developed a double retargeting strategy 47 
whereby gH carries the GCN4 peptide for retargeting to the non-cancer producer Vero-GCN4R cell 48 
line, and gD carries the scFv to HER2 for cancer retargeting. Here, we engineered double retargeted 49 
recombinants, which carry both the GCN4 peptide and the scFv to HER2 in gD. Novel, more 50 
advantageous detargeting strategies were devised, so as to optimize the cultivation of the double-51 
retargeted recombinants. Nectin1 detargeting was achieved by deletion of aa 35-39, 214-223, or 52 
219-223, and replacement of the deleted sequences with one of the two ligands. The latter two 53 
deletions were not attempted before. All recombinants exhibited the double retargeting to HER2 54 
and to the Vero-GCN4R cells, as well as detargeting from the natural receptors HVEM and nectin1. 55 
Of note, some recombinants grew to higher yields than others. The best performing recombinants 56 
carried a gD deletion as small as 5 amino acids, and grew to titers similar to those exhibited by the 57 
singly retargeted R-LM113, and by the non-retargeted R-LM5. This study shows that double 58 
retargeting through insertion of two ligands in gD is feasible and, when combined with appropriate 59 




There is increasing interest in oncolytic viruses, following FDA and EMA approval of the oncolytic 64 
HSV Oncovex
GM-CSF
, and, mainly, because they greatly boost the immune response to the tumor 65 
and can be combined with immunotherapeutic agents, particularly immune checkpoint inhibitors. A 66 
strategy to gain high cancer specificity and avoid virus attenuation is to retarget the virus tropism to 67 
cancer-specific receptors of choice. However, cultivation of retargeted oncolytics in cells 68 
expressing the cancer receptor may not be approvable by regulatory agencies. We devised a strategy 69 
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for their cultivation in non-cancer cells. Here, we describe a double retargeting strategy, based on 70 
the simultaneous insertion of two ligands in gD, one for retargeting to a producer, universal Vero 71 
cell derivative, one for retargeting to the HER2 cancer receptor. These insertions were combined 72 
with novel, minimally-disadvantageous detargeting modifications. The current and accompanying 73 
studies teach how to best achieve the clinical-grade cultivation of retargeted oncolytics. 74 
75 
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Oncolytic viruses have come of age (1-5) since the approval by FDA and EMA of an oncolytic 77 
herpes simplex virus (HSV), initially named Oncovex
GM-CSF
 or T-Vec, for the treatment of 78 
metastatic melanoma (6, 7). Several generations of oncolytic HSVs were designed and tested in 79 
preclinical assays and in clinical trials. Many of them achieve cancer specificity by virtue of 80 
attenuation, frequently obtained through the deletion of the γ134.5 gene, whose product counteracts 81 
the IFN and PKR response of the cell to the virus (7-10). In other examples, additional genes were 82 
deleted (11, 12). The resulting recombinants exhibited varying degrees of attenuation. A drawback 83 
of attenuation is that not all cancer cells sustain a robust replication of these viruses. 84 
An alternative strategy to attenuation has been to obtain cancer specificity through the 85 
modification of the HSV tropism and tropism retargeting to a cancer specific receptor of choice, 86 
coupled with detargeting from natural receptors (13-21). In our laboratory the targeted cancer 87 
receptor is HER2 (human epidermal growth factor receptor 2), expressed in breast, ovary, stomach, 88 
lung and other cancers (22). While the HER2-positive cancers are usually treated with anti-HER2 89 
monoclonal antibodies, exemplified by trastuzumab and pertuzumab, only a fraction of cancers is 90 
sensitive to this treatment, and resistance develops frequently (23).  91 
HSV enters cells through the concerted action of four envelope glycoproteins, named gD, 92 
gH/gL and gB, which are activated in a cascade fashion by interaction with cognate receptors and 93 
intermolecular signaling (24-29). Briefly, gD interacts alternatively with HVEM or nectin1 (30-32). 94 
The receptor-bound gD activates gH/gL, which is additionally activated by vβ6 or vβ8-integrins 95 
(33, 34). gH activation results in the displacement of gL (35), and is then transmitted to gB, which 96 
executes the fusion between the virion envelope and the cell membrane (36). In the retargeted 97 
viruses, a new ligand, exemplified by a single chain antibody to HER2, is engineered in gD, in gH, 98 
or in gB, while appropriate deletions in gD ensure the detargeting from gD natural receptors (13, 99 
15-17, 37, 38). The chimeric glycoproteins which carry the scFv to HER2 mediate HSV entry 100 
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through HER2. Because of the detargeting-retargeting these oncolytic HSVs strictly depend on 101 
HER2 for infection.  102 
For clinical grade preparations of retargeted oncolytic HSVs, it is advisable to avoid the 103 
virus cultivation in HER2-positive cancer cells. To meet these needs, we recently developed a 104 
system for the cultivation in non-cancer cells of HSVs retargeted to HER2, and, potentially, to any 105 
cancer-specific receptor of choice. The system is based on a double retargeting strategy. One 106 
retargeting is to the HER2, or any cancer receptor of choice. The other retargeting is by way of the 107 
20 aa long GCN4 peptide, which readdresses the tropism to Vero cells expressing the artificial 108 
receptor named GCN4R (39). The latter is made by a single chain antibody to GCN4 (40) fused to 109 
domains II, III, TM and C tail of nectin1. The choice of the Vero cells as recipients of GCN4R 110 
rested on the notion that wt-Vero cells have been approved by FDA for the clinical grade 111 
preparations of Oncovex
GM-CSF
 (commercial name Imlygic), the derivative named Vero-His is 112 
approved for clinical grade preparations of oncolytic Measles viruses (41), and, more generally, wt 113 
Vero are approved for growth of a number human vaccines. The R-213 recombinant was 114 
readdressed to GCN4R by engineering the GCN4 peptide in gH; simultaneously, it was readdressed 115 
to HER2 by insertion of the scFv to HER2 in gD, in place of aa 6-38 (39). This deletion detargets 116 
HSV tropism from HVEM and nectin1 (17). 117 
 The aims of this work were two-fold. First, to explore alternative ways to co-express the 118 
scFv to HER2 for cancer retargeting and the GCN4 peptide for in vitro cultivation in the Vero-119 
GCN4R cells. Second, to define novel, less disadvantageous detargeting strategies, so as to 120 




Double gD retargeting and novel detargeting. An aim of this work was to ascertain whether gD 125 
can simultaneously accept two retargeting moieties, the GCN4 peptide and the scFv to HER2. To 126 
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better accomplish this task, we reduced the size of the deletion in gD, so as to maintain the 127 
detargeted phenotype, and preserve gD sequences, and possibly gD structure, as much as possible. 128 
Our initial gD detargeted/retargeted viruses R-LM113 and R-LM249, which carry the deletion of aa 129 
6-38, or 61-218 (17, 19), respectively, were designed at times when the regions of interaction 130 
between gD and its receptors were known mainly through molecular biology approaches, and 131 
through structural information on HVEM-bound gD (32). Indeed, the deletion of aa 38 in R-LM113 132 
preceded the detailed knowledge of the nectin1 binding site in gD. Here, we took advantage of the 133 
information on gD contact area with nectin1, inferred from the structure of gD bound to nectin1, as 134 
determined by x-ray crystallography (42). According to the co-crystal structure, a tip in nectin1 135 
protrudes into a groove in gD, whose critical residues include the previously known Y38 and the 136 
adjacent residues, including H39, and residues 215 and 220-223. Those structural studies suggested 137 
two alternative possibilities for nectin1 detargeting. One was the deletion of aa 35-39. The other 138 
was the deletion of the region which includes aa 214-223 (42), not assayed before in detargeting 139 
studies. Here we removed aa 214-223, or 219-223. The HVEM detargeting was achieved by the 140 
simple insertion of the GCN4 peptide or of the scFv to HER2 between aa residues 24 and 25, which 141 
are part of the HVEM binding site (32). 142 
The list of double-insertion gD recombinants is reported in Table 1, which also summarizes 143 
essential phenotypic features of the recombinants. The genome backbone is shown in Fig. 1 A. The 144 
specific genotypes are shown in Fig. 1 B. The tropism was assayed in the HER2-positive cancer 145 
cells SK-OV-3, in wt-Vero cells and in Vero-GCN4R, which express the artificial receptor to 146 
GCN4 peptide (39) and in J cells derivatives. J cells express no receptor for HSV; derivatives 147 
expressing a single receptor - HER2, nectin1, HVEM - were described (16, 43). R-LM113, 148 
retargeted to HER2 but not to GCN4R, was included as control. The tropism of R-87, R-89, R-97, 149 
R-99, R-99-2 is shown in Fig. 2, A-F. Cumulatively, the results show the following. (i) All 150 
recombinants were detargeted from HVEM and from nectin1, since they failed to infect J-nectin1 151 
and J-HVEM cells. (ii) All recombinants were retargeted to HER2, as inferred by the infection of J-152 
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HER2 and SK-OV-3 cells, and by inhibition of infection by trastuzumab, the MAb to HER2 from 153 
which the scFv employed for retargeting was derived (44). This property is shared with R-LM113. 154 
(iii) All recombinants, except R-89, infected wt-Vero cells. This infection was inhibited by 155 
trastuzumab, hence most likely it occurred through the simian ortholog of hHER2. The genome 156 
sequence of Vero cell is incomplete, and, so far, there is no documentation of a HER2 homologue. 157 
However, Vero cells were isolated from an Africa Green Monkey (Chlorocebus sp.), and the 158 
sequence of the Chlorocebus genome contains the HER2 homologue (Chlorocebus sabaeus; 159 
REFSEQ: XM_008012845.1) with 98% identity with the human HER2 at the amino acid level. (iv) 160 
All recombinants infected Vero-GCN4R cells. This infection was only in part decreased by 161 
trastuzumab, indicating that it occurred in part through the GCN4 peptide present in the 162 
recombinants, and its interaction with the GCN4R. (v) There was no difference in the recombinant 163 
tropism whether the viruses were grown in Vero-GCN4R or in SK-OV-3 cells, as exemplified for 164 
R-87 and R-99 (Fig. 2 G-H). Altogether, the results indicate that double retargeting through the 165 
insertion of two different retargeting moieties in gD is feasible. All three nectin1-detargeting 166 
strategies based on 35-39, 214-223, or 219-223 were effective. The detargeting through 167 
deletion of the 214-223 or 219-223 regions were not attempted before. 168 
 Comparative growth of double gD-retargeted recombinants. We compared the yield of 169 
the above recombinants to those of the wt HSV-1(F), the wt-gD recombinant named R-LM5, and 170 
the singly HER2-retargeted R-LM113, in SK-OV-3 and in Vero-GCN4R cells. R-LM5 carries a wt-171 
gD, the BAC plus EGFP sequences, and is therefore the wt counterpart of the retargeted HSVs. A 172 
representative experiment (Fig. 3, A, B) shows that at 48 h after infection the yield of the 173 
recombinants R-87, R-97 and R-99-2 did not significantly differ one from the other, either in SK-174 
OV-3 or in Vero-GCN4R cells. We note that R-LM113 replicated for one passage in wt-Vero cells, 175 
and its Vero-GCN4R derivative; however, numerous efforts to passage serially R-LM113 in these 176 
cells were unsuccessful, and did not yield any progeny. The two recombinants with lower yields 177 
were R-89 and R-99. R-87 and R-89, representative of the best performing and least well 178 
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performing recombinants, respectively, were further analyzed with respect to the extent of virus 179 
release in the extracellular medium. Fig. 3 C, D shows that, for both viruses the extracellular virus 180 
yield at 48 h was about 1 log lower than the intracellular virus yield, as was the case for R-LM113. 181 
 Next, we analyzed the ability of the recombinants to form plaques, with respect to plaque 182 
size and plating efficiency. Fig. 4 A shows a typical plaque for each recombinant in Vero-GCN4R 183 
and SK-OV-3 cells. The average plaque size of the recombinants is shown in Fig. 4 B. All 184 
recombinants formed somewhat larger plaques in Vero-GCN4R than in SK-OV-3 cells. Also with 185 
respect to the number of plaques, the efficiency was somewhat higher in the Vero-GCN4R than in 186 
the SK-OV-3 (Fig 4 C). Altogether, these results show that the Vero-GCN4R cell line enables 187 
efficient spread of the recombinants.  188 
In the past, we observed that switching a virus from one cell line to a different cell line for 189 
replication may sometime result in a lower replication rate at earliest passages after the switch. 190 
Specifically, when a virus is grown in a certain cell line (e.g. Vero-GCN4R) and is then switched to 191 
another cell line (e.g. SK-OV-3), there may be a decrease in the efficiency of virus growth at very 192 
early passages. We analyzed whether the growth of R-87 and R-97 in Vero-GCN4R cells may 193 
affect the extent of replication in the cancer SK-OV-3 cells. R-87 and R-97 were grown in Vero-194 
GCN4R (R-87VG and R-97VG) or in SK-OV-3 cells (R-87SK and R-97SK), and then employed to 195 
infect SK-OV-3 cells.  Fig. 5 shows that R-87VG grew as efficiently as R-87SK in SK-OV-3 cells. 196 
Similarly, R-97VG grew as efficiently as R-97SK in SK-OV-3 cells. Thus, switching from Vero-197 
GCN4R to SK-OV-3 cells exerted no detrimental effect on the efficiency of viral growth. 198 
 199 
Cell killing ability of double gD retargeted recombinants. The above candidate oncolytic 200 
recombinants were tested for ability to exert cytotoxic activity towards SK-OV-3 and Vero-GCN4R 201 
cells. Fig. 6A shows all recombinants were cytotoxic for SK-OV-3 cells. The highest effect was 202 
exhibited by the recombinants which replicated better. All the recombinants were cytotoxic also for 203 
Vero-GCN4R cells (Fig. 6B). As expected, the exception was R-LM113 in Vero-GCN4R cells, 204 
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since the virus infects these cells at low efficiency. As noted earlier, the HER2 retargeted viruses 205 
infect Vero cells most likely through the simian HER2.  206 
 207 
Oncolytic efficacy of a double gD retargeted recombinant in immunocompetent mice. 208 
We selected R-87, one of the best performing double gD retargeted recombinants, to evaluate the 209 
oncolytic efficacy in immunocompetent mice. The animal model will be described elsewhere in 210 
detail under different co-authorship (45). Essentially, it consists of the Lewis lung murine 211 
carcinoma 1 (LLC-1) cells made transgenic for human HER2 (hHER2-LLC-1). The cancer cells 212 
were implanted in a strain of the syngeneic C57BL6 mice, which are transgenic for, hence tolerant 213 
to hHER2. Three days after implantation of the tumor cells, R-87 was administered intratumorally 214 
(i.t.) at 3-4 days distance, with 1 x 10
8
 PFU/injection, for a total of 4 treatments. As a comparison 215 
we included in the experiment the prototypic R-LM113 and R-317 described in the accompanying 216 
paper (46). Fig. 7 A-C shows that the antitumor efficacy of R-87 was very similar to those of R-217 
LM113 and of R-317, and the tumor size was significantly smaller than that in the untreated mice at 218 
28 d (Fig. 7 D). 219 
220 
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Recently we developed a system for the cultivation in non-cancer cells of clinical grade oncolytic 222 
HSVs retargeted to HER2, and, potentially, to any cancer-specific receptor of choice (39). The 223 
potentially universal system is based on a double retargeting strategy. One retargeting is to the 224 
cancer receptor, exemplified in our studies by HER2. The other retargeting is by way of the 20 aa 225 
long GCN4 peptide, which readdresses the tropism to Vero cells expressing the artificial GCN4R. 226 
Here, we asked whether a double retargeting via gD is feasible, and whether it can be optimized by 227 
means of a less disadvantageous detargeting strategy, designed on the structural analysis of the gD-228 
nectin1 co-crystal (42). We report that gD simultaneously accepts two different heterologous 229 
ligands for retargeting to two different receptors. The double retargeting can be combined with 230 
novel nectin1-detargeting strategies, based on small deletions at two different loci in gD. 231 
 Analysis of the panel of gD recombinants shows that all of them were simultaneously 232 
retargeted to the GCN4R and to the HER2, and detargeted from both HVEM and nectin1. A novel 233 
finding to emerge from this investigation is that the modifications to the locus around aa 214-223 is 234 
suitable for nectin1 detargeting, and retargeting. Each of the two heterologous receptors (HER2 and 235 
GCN4R) can be used alternatively to the other, and independently of the other. The recombinants 236 
switched readily from one cell system (GCN4R-positive cell) to the other (HER2-positive cell).  237 
Not all the insertion sites were equivalent, and the combination of ligand to insertion site can 238 
be optimized. This conclusion rests on the following examples.  239 
Comparison of R-87 versus R-97. R-87 and R-97 share the following properties. They carry 240 
the same deletion in gD (aa 35-39) for nectin1-detargeting. They carry one of the two inserts (the 241 
260 aa long scFv to HER2 or the 20 aa long GCN4 peptide) between aa 24 and 25 for HVEM 242 
detargeting. They differ in the relative position of the two inserts. Thus, in R-87 the gD deletion is 243 
replaced by the scFv, whereas in R-97 the deletion is replaced by the GCN4 peptide. A comparison 244 
of R-87 and R-97 shows that they grew to very similar yields. Hence, exchanging the short GCN4 245 
peptide and the scFv at anyone of these two positions was irrelevant with respect to growth capacity.  246 
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Comparison of R-89 versus R-99. R-89 and R-99 share the following properties. They carry 247 
the same deletion in gD (aa 214-223) for nectin1-detargeting. They carry one of the two inserts (the 248 
scFv to HER2 or the GCN4 peptide) between aa 24 and 25 for HVEM detargeting. They differ in 249 
the relative position of the two inserts. Thus, in R-89 the gD deletion is replaced by the scFv, 250 
whereas in R-99 the deletion is replaced by the GCN4 peptide. The R-89 and R-99 recombinants 251 
replicated in a similar manner, and there was no apparent effect of the relative position of the two 252 
inserts. Of note, the yields of R-89 and R-99 were lower than those of R-87 and R-97. Hence, a 10 253 
aa deletion at this locus does not enable a highly efficient replication.  254 
A comparison of R-97 versus R-99-2 sheds light on the effects of performing the deletion in 255 
the aa 35-39 locus versus the 219-223 locus. At 48 h these two recombinants replicated in a very 256 
similar manner in both SK-OV-3 and Vero-GCN4R cells, although a difference was seen at 24 h. 257 
Thus, a 5 aa deletion at anyone of these two loci results in very similar recombinants.  258 
Comparison of R-99 versus R-99-2. These two recombinants differ in that R-99-2 carries a 259 
smaller (5 aa) deletion than R-99 (10 aa deletion), and are otherwise identical. The important result 260 
here is that R-99-2 grew one log more that R-99, suggesting that the size of the deletion may be 261 
critical for a better preservation of gD functions. This may explain why R-87, R-97, and R-99-2, 262 
which carry 5 aa long deletions replicated to similar yields. Of note, the differences in virus yield 263 
were not fully recapitulated in the plaque size; the latter is influenced not only by virus replication 264 
but also by ability to perform cell-to-cell spread.  265 
The R-87 recombinant was selected to evaluate the antitumor efficacy in vivo, in an 266 
immunocompetent mouse model. In general, the murine cancer cells are not as permissive to HSV 267 
as the human cancer cells, hence this model underestimates the antitumor efficacy, a property 268 
shared with the vast majority of murine cancer models for oncolytic HSVs (47, 48). Here, the 269 
important result was that the anti-tumor efficacy of R-87 could not be differentiated from that of R-270 
LM113 and of the gB recombinant R-317, described in the accompanying paper (37). Thus, the 271 
replication properties in cell cultures are recapitulated in the in vivo anti-tumor efficacy, and a 272 
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recombinant carrying two retargeting moieties in gD is not at disadvantage relative to R-LM113, 273 
which carries a single retargeting moiety. Altogether, the double retargeting via gD was feasible. 274 
By optimizing the detargeting strategies we generated double-retargeted gD recombinants which 275 
replicated as efficiently as the singly retargeted R-LM113 or the non-detargeted R-LM5, and which 276 
exerted anti-tumor activity in vivo as efficiently as R-LM113. 277 
In an accompanying paper, we show that double retargeting is feasible also by insertion of 278 
the GCN4 peptide in gB, and of the scFv in gD (46); even in that study (46), a novel gD detargeting 279 
strategy was developed. In both studies, the comparison of a number of recombinants lead to 280 
optimization of double retargeted recombinants. Together with the previous finding that the double 281 
retargeting is achieved by insertion of the GCN4 peptide in gH, and of the scFv to HER2 in gD (39), 282 
current data indicate that several alternative strategies have become possible, now that we have 283 
enlarged the number of HSV glycoproteins that can serve as retargeting tools, and in the light of 284 
accurate knowledge of gD-receptor structures (42). All in all the double gD recombinants and the 285 
gB/gD simultaneous retargeting yielded recombinants which replicate at comparable yields and will 286 
help move the field of retargeted oncolytic HSVs into the translational phase.  287 
288 
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MATERIALS AND METHODS 289 
Viruses. R-LM5 and R-LM113 were described (17) (see Table 1, for summary of genotypes 290 
and tropism). R-LM5 carries wt-gD ORF, the bacterial artificial chromosome (BAC) sequences 291 
cloned in the UL3-UL4 intergenic region, as in the parental pYeBac 102 (49) and the enhanced 292 
green fluorescent protein (EGFP) ORF under the 27 promoter cloned within the BAC sequences 293 
(17). It is not detargeted/retargeted, therefore is the wt-counterpart of R-LM113, R-87, R-89, R-97, 294 
R-99, R-99-2. R-LM113 is identical to R-LM5, except that it carries a HER2-retargeted gD. In 295 
particular the deletion of aa 6-38 of mature gD which removes critical residues for interaction with 296 
HVEM and nectin1 and its replacement with the scFv to HER2 derived from trastuzumab (44), 297 
detargets the virus tropism from the natural receptors. wt HSV-1 F was described (50). 298 
Engineering of R-87, R-89, R-97, R-99, R-99-2.  299 
To engineer the gD double retargeted recombinants we constructed two precursor BAC, BAC 81 300 
and BAC 91, starting from LM55 BG BAC. BAC 81 carries GCN4 peptide between aa 24 and 25 301 
of gD, whereas BAC 91 carries scFv HER2 in the same position. The HSV-1 recombinants R-87, 302 
R-89 were derived from BAC 81 by insertion of the scFv HER2 in place of aa 35-39 (R-87), or in 303 
place of aa 214-223 (R-89). The recombinants R-97, R-99, R-99-2 were derived from BAC 91 by 304 
insertion of the GCN4 peptide in place of aa 35-39 (R-97), in place of aa 214-223 (R-99), or in 305 
place of aa 219-223 (R-99-2). See Fig.1 B and Table 1. The aa sequence of the GCN4 peptide was 306 
KNYHLENEVARLKKLG. The core YHLENEVARLKK residues represent the epitope 307 
recognized by the single chain antibody C11L34-H6 (PDB # 1P4B) (40). In the recombinant 308 
viruses, the GCN4 peptide was preceded and followed by GS linkers. The starting material for the 309 
engineering of BAC 81 and BAC 91 was LM55 BG BAC which carries LOX-P-bracketed 310 
pBeloBAC11 and eGFP sequences inserted between UL3 and UL4 of HSV-1 genome (17). The 311 
engineering was performed in bacteria by means of galK recombineering, in two steps (38, 51). In 312 
the first step, the galK cassette, with homology arms to gD, was inserted between aa 24 and 25 of 313 
mature gD. In the second step, the galK insert was replaced with the GCN4 peptide cassette to 314 
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generate the precursor BAC 81 or was replaced by the scFv HER2 cassette to generate the precursor 315 
BAC 91. 316 
To carry out the first step in the engineering of BAC 81, the galK cassette, with homology 317 
arms to gD was amplified by means of primers gD24_galK_f and gD25_galK_r (Table 2), using p-318 
galK plasmid as template. The PCR-amplified galK cassette was then electroporated into SW102 319 
bacteria, which carry the LM55 BG BAC, to generate BAC 80. To exclude galK false positive 320 
colonies, the recombinant clones were plated on Mac Conkey agar base plates, supplemented with 321 
1% galactose and 12 g/ml chloramphenicol, and checked by colony PCR. Colony PCR was carried 322 
out with primer galK_827_f and galK_1142_r (Table 2). To carry out the second step and generate 323 
the precursor BAC 81, a cassette encoding the GCN4 peptide (GenBank accession number 324 
AF416613.1) (40) bracketed by the downstream and upstream Gly-Ser linkers and by homology 325 
arms to gD was generated, through annealing and extension of the partially overlapping 326 
oligonucleotides gD24_GCN4_fB and gD25_GCN4_rB (Table 2). The oligonucleotides contained 327 
a silent BamHI restriction site, for screening purposes. The amplimer encoding the GCN4 cassette, 328 
with homology arms to gD, was electroporated into SW102 bacteria carrying BAC 80. The 329 
recombinant BAC was named BAC 81. Positive bacterial clones were checked by means of BamHI 330 
restriction analysis on colony PCR fragments, amplified with primers gD_ext_f and gD_ext_r 331 
(Table 2). 332 
The precursor BAC 91 carries the scFv to HER2 between aa 24 to 25 of gD. It was 333 
generated from BAC 80. First, the scFv HER2 cassette bracketed by homology arms to gD was 334 
amplified by means of primers gD24-scFvHer2-F and gD25-scFvHer2-R (Table 2). Bacterial 335 
colonies were checked for the presence of sequence of choice by means of colony PCR with 336 
primers gD_ext_f and scFv_456_r (Table 2). 337 
To engineer R-87 and R-89, the scFv HER2 was inserted in gD Δ35-39 (R-87), or in gD 338 
214-223 (R-89), as detailed for BAC 81, by means of oligonucleotides reported in Table 2. To 339 
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engineer R-97, R-99, and R-99-2, the GCN4 peptide was inserted in gD 35-39 (R-97), gD 214-340 
223 (R-99), or gD 219-223 (R-99-2) of BAC 91, by means of oligonucleotides reported in Table 2.  341 
To reconstitute the recombinant viruses, 500 ng of recombinant BAC DNA was transfected 342 
into the Vero-GCN4R cell line and SK-OV-3 cell line by means of Lipofectamine 2000 (Life 343 
Technologies), and then grown in these cells. Virus growth was monitored by green fluorescence. 344 
The structure of the recombinant was verified by sequencing the entire gD. Virus stocks were 345 
generated in Vero-GCN4R and SK-OV-3 and titrated in Vero-GCN4R and SK-OV-3 cells. All 346 
other recombinants were engineered by the same procedure, by means of oligonucleotides described 347 
in Table 2. 348 
Tropism of R-87, R-89, R-97, R-99, R-99-2. The indicated cells were infected with the 349 
indicated viruses at 1 PFU/cell, and monitored 24 h later with a Nikon Eclipse TS100 fluorescence 350 
microscope. Where indicated, infection was carried out in the presence of MAb to HER2 351 
(trastuzumab) at the concentration of 28 μg/ml. 352 
 Determination of virus growth and extent of viral progeny release. Vero-GCN4R and 353 
SK-OV-3 cells were infected with wt HSV-1 F, R-LM5, R-LM113, R-87, R-89, R-97, R-99, R-99-354 
2 at 0.1 PFU/cell. Unabsorbed virus was inactivated by rinsing the cells with a pH 3 solution (40 355 
mM citric acid, 10 mM KCl, 135 mM NaCl). Replicate cultures were frozen at 24 and 48 h after 356 
infection. Progeny virus (intracellular plus extracellular) was titrated in SK-OV-3 cells. Results are 357 
expressed as the mean of three independent experiments ± SD. In virus release experiments, 358 
replicate cultures of Vero-GCN4R or SK-OV-3 infected with R-LM113, R-87 or R-89 at 0.1 359 
PFU/cell were harvested 48 h after infection as cell lysates plus medium. Alternatively medium or 360 
cellular fractions were harvested separately. Progeny virus was titrated in SK-OV-3 cells. Results 361 
are expressed as the mean of three independent experiments ± SD. 362 
 Plating efficiency and relative plaque size. Replicate aliquots of R-LM5, R-LM113, R-87, 363 
R-89, R-97, R-99, R-99-2 were plated on Vero-GCN4R and SK-OV-3 cells and the number of 364 
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plaques was counted 3 days later. Results represent the mean of three independent infections ± SD. 365 
For plaque size determination, pictures of 6 individual plaques from each of the above samples 366 
were taken 3 days after infection. Plaque areas were measured with Nis Elements-Imaging Software 367 
(Nikon). Each result represents areas ± SD. 368 
 Cytotoxicity assay. SK-OV-3 and Vero-GCN4R cells were seeded in 96 well plates (8x10
3
 369 
cell/well) and infected with wt HSV-1 F, R-LM5, R-LM113, R-87, R-89, R-97, R-99, R-99-2 (3 370 
PFU/cell) or mock-infected. AlamarBlue (10 μl/well, Life Technologies) was added to the culture 371 
media at indicated times after infection and incubated for 4 h at 37°C. Plates were read at 560 and 372 
600 nm with GloMax Discover System (Promega Corporation). For each time point, cell viability 373 
was expressed as the percentage of alamarBlue reduction in infected versus uninfected cells, after 374 
subtraction of the background value (medium alone). Each point represents the average of at least 375 
triplicate samples ± SD. 376 
 In vivo anti-tumor efficacy. C57BL6 mice transgenic for and tolerant to hHER2, received 377 
from Jackson Laboratories, were implanted with the murine Lewis lung carcinoma 1 (LLC-1) cells 378 
made transgenic for hHER2 (hHER2-LLC-1), 0.2 x 10
6
 cells/mouse (45). Three days later mice 379 
received R-87, R-LM113 and R-317 as control viruses, peri-intratumorally (i.t.), four 380 
dosages/mouse at 3-4 days distance, 1 x 10
8
 PFU/injection, 5 mice for each treatment group. Tumor 381 
size was measured by means of a caliper at the indicated days as described (19). Animal 382 
experiments were performed according to European directive 2010/63/UE, Italian laws 116/92 and 383 
26/2014. Experimental protocols were reviewed and approved by the University of Bologna Animal 384 
Care and Use Committee (“Comitato per il Benessere degli Animali, COBA”), and approved by the 385 
Italian Ministry of Health, Authorization # 86/2017-PR to Prof. Anna Zaghini.   386 
387 
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FIGURE LEGENDS  558 
Fig. 1. Genome arrangement of recombinants generated in this study. (A) Prototypic genome 559 
arrangement of recombinants. Each recombinant carries the BAC sequence and the α27-promoter 560 
driven EGFP (enhanced green fluorescence protein), bracketed by LoxP sites, cloned in the UL3 561 
and UL4 intergenic region, the GCN4 peptide and the scFv to HER2 in appropriate sites of gD as 562 
detailed below. The Unique Long (UL) and Unique Short (US) portions of the genome, bracketed 563 
by terminal (TR) and internal repeats (IR), along with the location of gB and gH genes are shown. 564 
(B) Specific genotypic modifications in gD gene of each recombinant. 565 
 566 
Fig. 2. Tropism of R-87, R-89, R-97, R-99, and R-99-2 recombinants, and, for comparison, of R-567 
LM113 in the indicated cell lines. (A-F) The indicated cells were infected with R-87 (A), R-89 (B), 568 
R-97 (C), R-99 (D), R-99-2 (E) and for comparison, R-LM113 (F) at an MOI of 1 PFU/cell and 569 
monitored for EGFP expression by fluorescence microscopy 24 h post infection. J-cells express no 570 
receptor for wt HSV; J-HER2, J-nectin1, and J-HVEM express the indicated receptor. Infection was 571 
carried out in the absence of antibodies (no Ab), or in the presence of the humanized anti-HER2 572 
monoclonal antibody trastuzumab at a concentration of 28 μg/ml. (G-H) Tropism of R-87 (G) and 573 
R-99 (H) recombinants grown in Vero-GCN4R cell. Cells were infected and monitored for EGFP 574 
expression as described above. The panels were adjusted by means of Adobe Photoshop software to 575 
match one to the other in the final gallery. The level, brightness and contrast of each panel were 576 
adjusted as follow R-87 (A) panels a,b,c,f +35 +75 +100, panels d,e,g,h,i,j,k +35 +25 +100; R-89 577 
(B) panels a,b,e,f +35 +75 +100, panels c,g +35 +75 0, panels d,h,i,j,k +35 +25 +100; R-97 (C) 578 
panels a,b,e,f,g +35 +75 +100, panel c +35 +75 0, panels d,h +35 +25 0, panels i,j,k +35 +25 +100; 579 
R-99 (D) panels a,c,g +35 +75 0, panels b,e,f +35 +75 +100, panels d,h +35 +25 0, panels i,j,k +35 580 
+25 +100; R-99-2 (E) panels a,b,e,f +35 +75 +100, panels c,g +35 +75 0, panels d,h,i,j,k +35 +25 581 
+100; R-LM113 (F) panels a,b,e,f +35 +75 +100, panels c,g +35 +75 0, panels d,h,i,j,k +35 +25 582 
+100. R-87VG (G) panels a,b +50 +75 +100, panel c +35 +100 +0, panels d,e,f,g +50 +25 +100, 583 
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panels h,i,j,k +50 0 +100; R-99VG (H) panels a,b,e,f +35 +75 +100, panel c +35 +75 0, panels 584 
d,h,i,j,k +35 +25 +100, panel g +15 +75 0 585 
 586 
Fig. 3. Yield of R-87, R-89, R-97, R-99, and R-99-2 recombinants, and of R-LM5, R-LM113 and 587 
wt-HSV-1(F), for comparison. (A, B) SK-OV-3 (A) and Vero-GCN4R (B) cells were infected with 588 
the indicated viruses at 0.1 PFU/cell. Progeny virus collected at 24 or 48 h after infection was 589 
titrated in SK-OV-3 cells. Results represent the average of triplicates, ± SD. (C, D) Production of 590 
intracellular and extracellular R-87, R-89, and R-LM113 in SK-OV-3 (C) and in Vero-GCN4R (D) 591 
cells. Replicate cultures were infected as above. At 48 h after infection, media (extra) and cells 592 
(intra) were harvested separately, or together (intra + extra). Progeny virus was titrated in SK-OV-3 593 
cells. Results represent the average of triplicates, ± SD. 594 
 595 
Fig. 4. Plating efficiency of the indicated recombinants in Vero-GCN4R and SK-OV-3 cells. (A) A 596 
typical plaque is shown for each virus in the indicated cells. (B) Average plaque size of the 597 
indicated recombinants in Vero-GCN4R and SK-OV-3 cells. Six pictures were taken for each 598 
recombinants. Plaque areas were measured with Nis Elements-Imaging software (Nikon). (C) 599 
Replicate aliquots of viruses were plated in SK-OV-3 and Vero-GCN4R cells. Plaques were scored 600 
three days later. The relative number of plaques formed by each virus in the indicated cell line is 601 
reported as percentage of the number of plaques formed in SK-OV-3 cells. Results represent the 602 
average of triplicates, ± SD. The panels were adjusted by means of Adobe Photoshop software to 603 
match one to the other in the final gallery. The level, brightness and contrast of each panel were 604 
adjusted as follow. Panel a +30 +50 +100, panels b,h,n +20 +50 +100, panels c,d,k,l +50 +25 +50, 605 
panels e,f +35 +20 +100, panel g +35 +50 +100, panels i,j +35 +25 +100, panel m +30 +75 +100. 606 
 607 
Fig. 5. Comparative yield of R-87 and R-97 pre-cultivated in SK-OV-3 or Vero-GCN4R cells. R-87 608 
and R-97 were cultivated in SK-OV-3 (R-87SK, R-97SK) or in Vero-GCN4R (R-87VG, R-97VG) cells 609 
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and employed to infect SK-OV-3 cells at 0.1 PFU/cell. Progeny virus harvested at 24 or 48 h after 610 
infection was titrated in SK.OV-3 cells. Results represent the average of triplicates, ± SD. 611 
 612 
Fig. 6. Cell killing ability of the indicated viruses for SK-OV-3 and Vero-GCN4R cells. (A, B) SK-613 
OV-3 (A) or Vero-GCN4R (B) cells were infected with the indicated recombinants, or with HSV-614 
1(F), R-LM5, or R-LM113 as controls, at 3 PFU/cell. Cell viability was quantified by alamarBlue 615 
assay at the indicated days after infection. Results represent a typical experiment; each sample is the 616 
average of triplicate assay ± SD. 617 
 618 
Fig. 7. Antitumor activity of R-87. A-C. Groups of 5 mice from the hHER2-transgenic C57BL6 619 
strain were implanted with hHER2-LLC-1 cells (0.2 x 10
6
 cell) in the left flank. Starting 3 d later, 620 
mice received four intratumoral treatments with the indicated viruses, at 3-4 d distance, 1 x 10
8
 621 
PFU/treatment.. Tumor volumes for each treatment group are shown. D. Distribution of the tumor 622 
size at 28 d after the initial treatment. This experiment is the same as that shown in Fig. 6 of the 623 
accompanying paper (37). 624 
625 
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R-87 24-25  Δ35-39 + + This paper 
R-89 24-25  Δ214-223 + + This paper 
R-97 Δ35-39  24-25 + + This paper 
R-99 Δ214-223 24-25 + + This paper 
R-99-2 Δ219-223 24-25  + + This paper 
R-LM113 none Δ6-38 + + (17) 
R-LM5 none 
no scFv,  
no deletion 
- - (17) 
 627 
Table 2. Oligonucleotides employed to engineer the indicated recombinants. 628 
BAC-81 GCN4 peptide cassette inserted between aa 24 and 25 of mature gD of LM55 BAC 
1) galK insertion in 
gD 24-25 
 
Forward: gD24_galK_f CTC TCA AGA TGG CCG ACC CCA ATC GCT TTC GCG 
GCA AAG ACC TTC CGG TCC CTG TTG ACA ATT AAT CAT CGG CA 
Reverse: gD25_galK_r TGG ATG TGG TAC ACG CGC CGG ACC CCC GGA GGG 
TCG GTC AGC TGG TCC AGT CAG CAC TGT CCT GCT CCT T 
2) colony PCR for 
screening 
Forward: galK_827_f GCG TGA TGT CAC CAT TGA AG  
Reverse: galK_1142_r TAT TGT TCA GCG ACA GCT TG 
3) GCN4 cassette 
insertion in place 
of galK 
 
Forward: gD24_GCN4_fB CTC TCA AGA TGG CCG ACC CCA ATC GCT TTC 
GCG GCA AAG ACC TTC CGG TCG GAT CCA AGA ACT ACC ACC TGG AGA 
ACG AGG TGG CCA GAC TGA AGA AGC TGG TGG GCA GC  
Reverse: gD25_GCN4_rB TGG ATG TGG TAC ACG CGC CGG ACC CCC GGA 
GGG TCG GTC AGC TGG TCC AGG CTG CCC ACC AGC TTC TTC AGT CTG 
GCC ACC TCG TTC TCC AGG TGG TAG TTC TTG GAT CC 
4) colony PCR for 
screening  
Forward: gD_ext_f TCC ATA CCG ACC ACA CCG ACG AAT CCC  
Reverse: gD_ext_r GAG TTT GAT ACC AGA CTG ACC GTG 
R-87 scFv HER2 inserted in gD Δ35-39 of BAC 81 
1) galK insertion in 
gD Δ35-39 
Forward: galK_gD35_F TGA AGA AGC TGG TGG GCA GCC TGG ACC AGC 
TGA CCG ACC CTC CGG GGG TCC CTG TTG ACA ATT AAT CAT CGG CA 
Reverse: galK_gD39_R GTG ATC GGG AGG CTG GGG GGC TGG AAC GGG 
TCT GGT AGG CCC GCC TGG ATT CAG CAC TGT CCT GCT CCT T 
2) scFv HER2 
insertion in place 
of galK 
Forward: gD-34-scFvHER2-F TGA AGA AGC TGG TGG GCA GCC TGG ACC 
AGC TGA CCG ACC CTC CGG GGG TCG AGA ATT CCG ATA TCC AGA T 
Reverse: gD-40-scFvHER2-R GTG ATC GGG AGG CTG GGG GGC TGG AAC 
GGG TCT GGT AGG CCC GCC TGG ATG GAT CCA CCG GAA CCA GAG C 
3) colony PCR for 
screening  
Forward: gD_ext_f TCC ATA CCG ACC ACA CCG ACG AAT CCC 
Reverse: scFv_456_r AGC TGC ACA GGA CAA ACG GAG TGA GCC CCC 
R-89 scFv HER2 inserted in gD Δ214-223 of BAC 81 
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1) galK insertion in 
gD Δ214-223 
Forward: galK_gD214_F CCT ACC AGC AGG GGG TGA CGG TGG ACA GCA 
TCG GGA TGC TGC CCC GCT TCC CTG TTG ACA ATT AAT CAT CGG CA 
Reverse: galK_gD223_R CTC GTG TAT GGG GCC TTG GGC CCG TGC CAC 
CCG GCG ATC TTC AAG CTG TAT CAG CAC TGT CCT GCT CCT T 
2) scFv HER2 
insertion in place 
of galK 
Forward: gD213-scFvHER2f CCT ACC AGC AGG GGG TGA CGG TGG ACA 
GCA TCG GGA TGC TGC CCC GCT TCG AGA ATT CCG ATA TCC AGA T  
Reverse: gD224-scFvHER2r CTC GTG TAT GGG GCC TTG GGC CCG TGC CAC 
CCG GCG ATC TTC AAG CTG TAG GAT CCA CCG GAA CCA GAG C 
3) colony PCR for 
screening  
Forward: gDintforw CCC TAC AAC CTG ACC ATC GCT TGG  
Reverse: scFv_456_r AGC TGC ACA GGA CAA ACG GAG TGA GCC CCC 
BAC 91 scFv HER2 cassette inserted between aa 24 and 25 of mature gD of LM55 BAC 
1) scFv HER2 
insertion in place 
of galK 
Forward: gD24-scFvHer2-F CTC TCA AGA TGG CCG ACC CCA ATC GCT TTC 
GCG GCA AAG ACC TTC CGG TCG AGA ATT CCG ATA TCC AGA TG  
Reverse: gD25-scFvHer2-R TGG ATG TGG TAC ACG CGC CGG ACC CCC GGA 
GGG TCG GTC AGC TGG TCC AGG GAT CCA CCG GAA CCA GAG C 
2) Colony PCR for 
screening  
Forward: gD_ext_f TCC ATA CCG ACC ACA CCG ACG AAT CCC  
Reverse: scFv_456_r AGC TGC ACA GGA CAA ACG GAG TGA GCC CCC 
R-97 GCN4 inserted in gD Δ35-39 of BAC 91 
1) galK insertion in 
gD Δ35-39 
Forward: gD35-galK-F GCT CTG GTT CCG GTg GaT CCC TGG ACC AGC TGA 
CCG ACC CTC CGG GGG TCC CTG TTG ACA ATT AAT CAT CGG CA  
Reverse: gD39-galK-R GTG ATC GGG AGG CTG GGG GGC TGG AAC GGG TCT 
GGT AGG CCC GCC TGG ATT CAG CAC TGT CCT GCT CCT T 
2) GCN4 insertion 
in place of galK 
Forward: gD35-GCN4-F GCT CTG GTT CCG GTg GaT CCC TGG ACC AGC TGA 
CCG ACC CTC CGG GGG TCG GAT CCA AGA ACT ACC ACC TGG AGA ACG 
AGG TGG CCA GAC TGA AGA AGC TGG TGG GCA GC  
Reverse: gD39-GCN4-R GTG ATC GGG AGG CTG GGG GGC TGG AAC GGG 
TCT GGT AGG CCC GCC TGG ATG CTG CCC ACC AGC TTC TTC AGT CTG 
GCC ACC TCG TTC TCC AGG TGG TAG TTC TTG GAT CC 
3) colony PCR for 
screening  
Forward: scFv4D5 651_f GGA CAC TGC CGT CTA TTA TTG TAG CCG CT 
Reverse: gDintrev CCA GTC GTT TAT CTT CAC GAG CCG 
R-99 GCN4 inserted in gD Δ214-223 of BAC 91 
1) galK insertion in 
gD Δ214-223 
 
Forward: galK_gD214_F CCT ACC AGC AGG GGG TGA CGG TGG ACA GCA 
TCG GGA TGC TGC CCC GCT TCC CTG TTG ACA ATT AAT CAT CGG CA  
Reverse: galK_gD223_R CTC GTG TAT GGG GCC TTG GGC CCG TGC CAC 
CCG GCG ATC TTC AAG CTG TAT CAG CAC TGT CCT GCT CCT T 
2) GCN4 insertion 
in place of galK 
Forward: gD213-GCN4-F CCT ACC AGC AGG GGG TGA CGG TGG ACA GCA 
TCG GGA TGC TGC CCC GCT TCG GAT CCA AGA ACT ACC ACC TGG AGA 
ACG AGG TGG CCA GAC TGA AGA AGC TGG TGG GCA GC  
Reverse: gD224-GCN4-R CTC GTG TAT GGG GCC TTG GGC CCG TGC CAC 
CCG GCG ATC TTC AAG CTG TAG CTG CCC ACC AGC TTC TTC AGT CTG 
GCC ACC TCG TTC TCC AGG TGG TAG TTC TTG GAT CC 
3) Colony PCR for  Forward: gDintforw CCC TAC AAC CTG ACC ATC GCT TGG  
Reverse: HSV_139688_r CCG ACT TAT CGA CTG TCC ACC TTT CCC 
 on F

















R-99-2 GCN4 inserted in gD Δ219-223 of BAC 91 
1) galK insertion in 
gD Δ214-223 
Forward: galK_gD214_F CCT ACC AGC AGG GGG TGA CGG TGG ACA GCA 
TCG GGA TGC TGC CCC GCT TCC CTG TTG ACA ATT AAT CAT CGG CA  
Reverse: galK_gD223_R CTC GTG TAT GGG GCC TTG GGC CCG TGC CAC 
CCG GCG ATC TTC AAG CTG TAT CAG CAC TGT CCT GCT CCT T 
2) GCN4 insertion 
in place of galK 
 
Forward: gD219-GCN4-F CCT ACC AGC AGG GGG TGA CGG TGG ACA GCA 
TCG GGA TGC TGC CCC GCT TCA TCC CCG AGA ACC AGC GCG GAT CCA 
AGA ACT ACC ACC TGG AGA ACG AGG TGG CCA GAC TGA AGA AGC TGG  
Reverse: gD224-GCN4-R CTC GTG TAT GGG GCC TTG GGC CCG TGC CAC 
CCG GCG ATC TTC AAG CTG TAG CTG CCC ACC AGC TTC TTC AGT CTG 
GCC ACC TCG TTC TCC AGG TGG TAG TTC TTG GAT CC 
3) colony PCR for 
screening  
Forward: gDintforw CCC TAC AAC CTG ACC ATC GCT TGG  
Reverse: HSV_139688_r CCG ACT TAT CGA CTG TCC ACC TTT CCC 
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